Effects of blood glucose on delay discounting, food intake and counterregulation in lean and obese men

Johanna Klement⁎,1, Britta Kuberaa, Jonas Eggelingb, Christin Rädela, Christin Wagnera, Soyoung Q. Parkb, Achim Petersa

a Department of Internal Medicine 1, University of Lübeck, Lübeck, Germany
b Department of Psychology, Social Psychology & Decision Neuroscience, University of Lübeck, Lübeck, Germany

ARTICLE INFO

Keywords:
Delay discounting
Impulsivity
Glucose metabolism
Hypoglycemia counterregulation
Food intake
Obesity

ABSTRACT

Background: Delay discounting as a measure of impulsivity has been shown to be higher in obesity with an association of increased food intake. Moreover, obese humans showed a higher wanting for high-calorie food than lean men when blood glucose concentrations were low. First studies linking blood glucose levels to delay discounting yielded mixed results. We hypothesized that obese people—in comparison to lean men—have a relative lack of energy, especially when blood glucose levels are low, that results in higher levels of delay discounting, food intake and hormonal counterregulation.

Methods: We investigated 20 lean and 20 obese healthy young men in a single-blind balanced cross-over design. With a standardized glucose clamp technique, subjects underwent a hypoglycemic state in one condition and a euglycemic state in the control condition. Regularly, blood was sampled for assessment of hormonal status, and questionnaires were filled out to assess delay discounting and symptom awareness. After normalizing blood glucose concentrations, subjects were free to eat from a standardized test buffet, followed by a snack test.

Results: Delay discounting was higher in obese than in lean men throughout experiments (p < 0.03). However, we did not observe significant discounting differences between glucose conditions (p > 0.1). Furthermore, the discounting performance did not correlate with food intake from the test buffet or snack test (p > 0.3). As a response to hypoglycemia, hormonal counterregulation was pronounced in both weight groups (p < 0.03), but responses of ACTH, norepinephrine and glucagon were stronger in obese compared to lean men (p < 0.03).

Conclusions: Our data suggest that augmented delay discounting is a robust feature in obesity that is not linked to glucose levels or actual food intake. With our systematically controlled approach, combining performance in delay discounting with regard to distinct blood glucose levels, different weight groups, counterregulatory behavior and food intake, our results imply that delay discounting is not susceptible to fluctuations of blood glucose and do not support the assumption that a low body’s energy content leads to increased impulsivity. Further replications including women and larger sample sizes are needed to corroborate our data.

1. Introduction

Given the increasing number of overweight and obesity, the understanding of the reasons for unhealthy diets is important (Collaborators et al., 2017). 'Delay discounting' is discussed as a marker of self-control and impulsivity that receives growing attention as a possible factor for unhealthy choices (Barlow et al., 2016; Story et al., 2014). People who 'discount' the value of the reward in the future, prefer smaller immediate rewards over larger rewards available after a delay. Relating to food intake, some unhealthy foods rich in sugar and fat offer immediate reward, whereas healthy diets may offer delaying benefits like maintaining weight, which let researchers hypothesize a link between individual delay discounting rates and food intake (Barlow et al., 2016). Several studies revealed a positive association of delay discounting rates with total energy intake (Appelhans et al., 2012; Rollins et al., 2010), frequency of fast food consumption (Garza et al.,...
2. Materials and methods

2.1. Participants

Twenty lean men (mean ± SEM age: 24.9 ± 0.6 years; BMI: 22.2 ± 0.4 kg/m²) and twenty obese men (mean age: 25.4 ± 0.8 years; BMI: 36.8 ± 1.4 kg/m²) of Caucasian descent participated in the experiments (p > 0.5 for age, p < 0.002 for BMI for group comparisons). Physical or mental disease, and abuse of alcohol, nicotine or drugs were excluded by medical history, physical examination, and laboratory tests. Other exclusion criteria were nightshifts, exceptional stress during the past two weeks, and fasting blood glucose levels > 6.1 mmol/l to exclude prediabetes. The study was approved by the Ethics committee of the University of Lübeck (reference number 12-171) and all subjects provided their written informed consent before participation.

2.2. Experimental design and clamp procedure

Each subject participated in two sessions (euglycemic and hypoglycemic clamp), separated by an interval of at least two weeks. The study was performed in a single-blind design and the order of the sessions was balanced across subjects.

After an overnight fast, participants arrived at the medical research unit at 7:45 a.m. Experiments took place in a sound attenuated room with the subjects resting on a bed. One venous catheter was placed in each arm. Both cannulas were connected to long thin tubes that enabled blood sampling and the infusion of glucose and insulin from an adjacent room without the awareness of the subject. A microphone and video camera were installed for communication and observation purposes.

After a 90 min baseline period, at 09:15 a.m., an insulin bolus of 10 mU/kg body weight of human insulin (Insumin® Rapid, Sanofi-Aventis, Frankfurt, Germany) was administered for two minutes followed by a constant rate infusion of 1.5 mU/kg/min. Glucose concentrations were measured every five minutes in whole blood (HemoCue, Angelholm, Sweden) and a solution of 20% glucose was infused at variable rates. Blood pressure, heart rate and physical well-being were continuously monitored. After 45 min, at 10:00 a.m., glucose target concentrations were achieved (target concentrations of ~100 mg/dl for the euglycemic session and ~50 mg/dl for the hypoglycemic session). These concentrations were maintained for 45 min. During this time, the study participant filled out the questionnaires for delay discounting and symptom awareness. At 10:40 a.m., insulin infusion was stopped, and euglycemia was re-established by infusion of glucose within the next 30 min. Thereafter, subjects were offered a rich test buffet for the next 30 min, followed by a snack test lasting 10 min.

Blood samples were drawn every 10 min during the plateau and every 30 min before and after the plateau to determine concentrations of plasma glucose, insulin, C-peptide, ACTH, cortisol, growth hormone, glucagon, and catecholamines. Blood samples were centrifuged and plasma as well as serum were stored at ~80 °C until assay.

2.3. Delay discounting task and symptom scores

For assessing delay discounting, participants performed a 27-item Monetary Choice Questionnaire (MCQ) once during baseline (09:00 a.m.) and once during the euglycemic or hypoglycemic plateau (10:30 a.m.). This established questionnaire measures delay discounting by asking individuals to choose between smaller rewards available immediately and larger rewards available after a delay (Kirby et al., 1999). Individual indifference points were determined and discounting rates (overall k-values) calculated using an excel-based spreadsheet tool provided by Kaplan et al. (2016). Logarithmic transformations of k-values were performed to approximate a normal distribution for use with parametric statistical analyses.

Subjective symptom awareness was rated on a 10-point scale twice during baseline, twice during the plateau, and once after finishing the test buffet. The questionnaire assesses symptoms that have previously shown to be sensitive to hypoglycemia and can be grouped into neuroglycopenic symptoms (dizziness, tingling, blurred vision, difficulty in thinking, faintness) and autonomic symptoms (anxiety, palpitation, hunger, sweating, irritability, tremor (Mitrikou et al., 1991)).

2.4. Analyses of blood parameters

Plasma glucose was measured in fluoride plasma (Roche-Diagnostic, Grenzach, Germany). Routine assays were used for the measurements of insulin, C-peptide, cortisol, adrenocorticotropic hormone (ACTH), human growth hormone (hGH) (all Immulite, Siemens, Erlangen, Germany) and glucagon (RIA, IBL International, Hamburg, Germany). Plasma epinephrine and norepinephrine concentrations were measured by standard high-performance liquid chromatography (Chromsystems, Munich, Germany).
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزار مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات